ALEXANDRIA, VA.–Although there are many parameters remaining to be defined for biosimilars, according to speakers at CBI’s 11th Summit on Biosimilars, the Centers for Medicare & Medicaid Services (CMS) is actively working on defining its policies.
FEBRUARY 2, 2016
CMS Moves on Biosimilar Reimbursement